cDNA cloning of a major allergen from timothy grass (P characterization of the recombinant Phl pV allergen

Journal of Immunology 151, 4773-81

Citation Report

#	Article	IF	CITATIONS
1	Major allergen Phl p Va (timothy grass) bears at least two different IgE-reactive epitopes. Journal of Allergy and Clinical Immunology, 1994, 94, 173-181.	2.9	47
2	IgE-binding capacity of recombinant timothy grass (Phleum pratense) pollen allergens. Journal of Allergy and Clinical Immunology, 1994, 94, 88-94.	2.9	61
3	Complementary DNA cloning of the major allergenPhl p I from timothy grass (Phleum pratense); recombinantPhl p I inhibits IgE binding to group I allergens from eight different grass species. Journal of Allergy and Clinical Immunology, 1994, 94, 689-698.	2.9	119
4	Effects of IL-4 and IL-13 on total and allergen specific IgE production by cultured PBMC from allergic patients determined with recombinant pollen allergens. Clinical and Experimental Allergy, 1995, 25, 879-889.	2.9	28
5	Pollen allergen homologues in barley and other crop species. Clinical and Experimental Allergy, 1995, 25, 66-72.	2.9	29
6	Basic and practical aspects of recombinant allergens. Allergy: European Journal of Allergy and Clinical Immunology, 1995, 50, 384-391.	5.7	125
7	Recombinant allergens for diagnosis and therapy of allergic diseases. Current Opinion in Immunology, 1995, 7, 751-756.	5.5	118
8	Major allergen <i>Phl p</i> Vb in timothy grass is a novel pollen RNase. FEBS Letters, 1995, 363, 6-12.	2.8	69
9	Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. Journal of Allergy and Clinical Immunology, 1996, 97, 95-103.	2.9	43
10	Identification of a 60 kd cross-reactive allergen in pollen and plant-derived food. Journal of Allergy and Clinical Immunology, 1996, 98, 938-947.	2.9	81
11	Expression of Zm13, a pollen specific maize protein, in <i>Escherichia coli</i> reveals IgEâ€binding capacity and allergenic potential. FEBS Letters, 1996, 381, 217-221.	2.8	13
12	Cloning and expression pattern of Hor v 9, the group 9 pollen isoallergen from barley. Gene, 1996, 182, 53-62.	2.2	8
13	Application of reversed-phase high-performance liquid chromatography in the purification of major allergens from grass pollen. Journal of Immunological Methods, 1996, 194, 27-34.	1.4	6
14	Serological and skinâ€ŧest diagnosis of birch pollen allergy with recombinant <i>Bet v</i> I, the major birch pollen allergen. Clinical and Experimental Allergy, 1996, 26, 50-60.	2.9	73
15	Detection of allergenâ€specific IgE in tears of grass pollenâ€allergic patients with allergic rhinoconjunctivitis. Clinical and Experimental Allergy, 1996, 26, 79-87.	2.9	36
16	Overview on denominated allergens. Clinical and Experimental Allergy, 1996, 26, 494-516.	2.9	36
17	Immunological and structural similarities among allergens: Prerequisite for a specific and componentâ€based therapy of allergy. Immunology and Cell Biology, 1996, 74, 187-194.	2.3	57
18	Construction of a Combinatorial IgE Library from an Allergic Patient. Journal of Biological Chemistry, 1996, 271, 10967-10972.	3.4	82

CITATION REPORT

#	Article	IF	CITATIONS
19	Le répertoire des allergènes recombinants. Revue Francaise D'allergologie Et D'immunologie Clinique, 1997, 37, 1083-1092.	0.1	1
20	The most common phenotypes of sensitization to inhalant allergens in childhood. Clinical and Experimental Allergy, 1997, 27, 646-652.	2.9	3
21	Investigation of Different Recombinant Isoforms of Grass Group-V Allergens (Timothy Grass Pollen) Isolated by Low-Stringency cDNA Hybridization - Antibody Binding Capacity and Allergenic Activity. FEBS Journal, 1997, 247, 217-223.	0.2	25
22	Risk and safety of immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 1998, 53, 473-476.	5.7	8
23	Detection and quantification of group 4 allergens in grass pollen extracts using monoclonal antibodies. Clinical and Experimental Allergy, 1998, 28, 799-807.	2.9	39
24	Mapping of Tâ€cell epitopes of Phl p 5: evidence for crossreacting and nonâ€crossreacting Tâ€cell epitopes within Phl p 5 isoallergens. Clinical and Experimental Allergy, 1998, 28, 1538-1548.	2.9	29
25	MOLECULAR BIOLOGY OF ASPERGILLUS ALLERGENS. Immunology and Allergy Clinics of North America, 1998, 18, 601-618.	1.9	10
26	How far can we simplify in vitro diagnostics for grass pollen allergy?: A study with 17 whole pollen extracts and purified natural and recombinant major allergens. Journal of Allergy and Clinical Immunology, 1998, 102, 184-190.	2.9	98
27	Calciumâ€dependent immunoglobulin E recognition of the apo―and calciumâ€bound form of a crossâ€reactive two EFâ€hand timothy grass pollen allergen, Phl p 7. FASEB Journal, 1999, 13, 843-856.	0.5	105
28	Antisense-mediated silencing of a gene encoding a major ryegrass pollen allergen. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11676-11680.	7.1	70
29	Component-Resolved Diagnosis (CRD) of Type I Allergy with Recombinant Grass and Tree Pollen Allergens by Skin Testing. Journal of Investigative Dermatology, 1999, 113, 830-837.	0.7	70
30	An immunoglobulin-like fold in a major plant allergen: the solution structure of Phl p 2 from timothy grass pollen. Structure, 1999, 7, 943-952.	3.3	46
31	<i>Phleum pratense</i> â€specific T cells of allergic rhinitis patients display a broader recognition pattern than <i>Phleum pratense</i> â€specific serum immunoglobulin E. Clinical and Experimental Allergy, 2000, 30, 242-254.	2.9	5
32	Complementary DNA cloning and expression of a newly recognized high molecular mass allergen Phl p 13 from timothy grass pollen (<i>Phleum pratense</i>). Clinical and Experimental Allergy, 2000, 30, 324-332.	2.9	35
33	The high molecular mass allergen fraction of timothy grass pollen (Phleum pratense) between 50-60 kDa is comprised of two major allergens: Phl p 4 and Phl p 13. Clinical and Experimental Allergy, 2000, 30, 1395-1402.	2.9	31
34	What are the important allergens in grass pollen that are linked to human allergic disease?. Clinical and Experimental Allergy, 2000, 30, 1335-1341.	2.9	68
35	Distribution of specific serum IgE to recombinant pollen allergens (rPhlp1, rPhlp2, rPhlp5, and rBetv2) and their relationship to each other and to their natural counterparts in patients allergic to grass pollen. Allergology International, 2000, 49, 93-97.	3.3	5
36	Regulation of the IgE allergic immune response by humoral and cellular factors. Apmis, 2000, 108, 7-43.	2.0	3

#	Article	IF	CITATIONS
37	A Human Monoclonal IgE Antibody Defines a Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5: Molecular, Immunological, and Structural Characterization of the Epitope-Containing Domain. Journal of Immunology, 2000, 165, 3849-3859.	0.8	77
38	Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: A study performed with purified recombinant pollen allergens. Journal of Allergy and Clinical Immunology, 2000, 105, 803-813.	2.9	47
39	Measurement of IgE antibodies against purified grassâ€pollen allergens (Phl p 1, 2, 3, 4, 5, 6, 7, 11, and 12) in sera of patients allergic to grass pollen. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1180-1185.	5.7	57
40	Skin Test Results but not Serology Reflect Immediate Type Respiratory Sensitivity: A Study Performed with Recombinant Allergen Molecules. Journal of Investigative Dermatology, 2001, 117, 848-851.	0.7	96
41	Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB Journal, 2002, 16, 414-416.	0.5	420
42	Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB Journal, 2002, 16, 1301-1303.	0.5	66
43	Purification, Structural and Immunological Characterization of a Timothy Grass (Phleum pratense) Pollen Allergen, Phl p 4, with Cross-Reactive Potential. Biological Chemistry, 2002, 383, 1383-96.	2.5	21
44	Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. Journal of Allergy and Clinical Immunology, 2002, 110, 102-109.	2.9	156
45	Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. European Journal of Immunology, 2002, 32, 270-280.	2.9	76
46	Hypoallergenic derivatives of major grass pollen allergens for allergy vaccination. Immunology and Cell Biology, 2003, 81, 86-91.	2.3	20
47	Allergenâ€specific immunotherapy with a monophosphoryl lipid Aâ€adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapyâ€induced blocking antibodies. Clinical and Experimental Allergy, 2003, 33, 1198-1208.	2.9	244
48	Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergenâ€specific serum immunoglobulin E. Clinical and Experimental Allergy, 2003, 33, 1443-1449.	2.9	166
49	Molecular Characterization of Polygalacturonases as Grass Pollen-Specific Marker Allergens: Expulsion from Pollen via Submicronic Respirable Particles. Journal of Immunology, 2004, 172, 6490-6500.	0.8	50
50	Human monoclonal antibody–based quantification of group 2 grass pollen allergens. Journal of Allergy and Clinical Immunology, 2004, 113, 470-474.	2.9	24
51	Mapping of conformational IgE epitopes on Phl p 5a by using mimotopes from a phage display library. Journal of Allergy and Clinical Immunology, 2004, 114, 1294-1300.	2.9	57
52	Assays for measuring in vitro basophil activation induced by recombinant allergens. Methods, 2004, 32, 265-270.	3.8	43
53	Affinity determinations of purified IgE and IgG antibodies against the major pollen allergens Phl p 5a and Bet v 1a: Discrepancy between IgE and IgG binding strength. Immunology Letters, 2005, 97, 81-89.	2.5	42
54	The Major Grass Pollen Group 5 Allergen from <i>Dactylis glomerata </i> and Its C-Terminal Split Product Both Behave as Dimers: Implications for Allergen Standardization. International Archives of Allergy and Immunology, 2005, 136, 113-122.	2.1	11

#	Article	IF	CITATIONS
55	The Human IgE-encoding Transcriptome to Assess Antibody Repertoires and Repertoire Evolution. Journal of Molecular Biology, 2006, 362, 212-227.	4.2	39
56	Allergenâ€induced interleukinâ€9 production <i>in vitro</i> : correlation with atopy in human adults and comparison with interleukinâ€5 and interleukinâ€13. Clinical and Experimental Allergy, 2006, 36, 174-182.	2.9	44
57	Structural Characterization of Pollen Allergens. Clinical Reviews in Allergy and Immunology, 2006, 30, 73-96.	6.5	11
58	Allergen cleavage by effector cellâ€derived proteases regulates allergic inflammation. FASEB Journal, 2006, 20, 967-969.	0.5	25
59	Gene gun immunization with clinically relevant allergens aggravates allergen induced pathology and is contraindicated for allergen immunotherapy. Molecular Immunology, 2007, 44, 1879-1887.	2.2	20
60	Exposure to a farming environment has allergen-specific protective effects on TH2-dependent isotype switching in response to common inhalants. Journal of Allergy and Clinical Immunology, 2007, 119, 351-358.	2.9	71
61	Generation of a low Immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a. Clinical and Experimental Allergy, 2007, 37, 441-450.	2.9	14
63	Review article: From allergen genes to new forms of allergy diagnosis and treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 299-309.	5.7	33
64	Characterization of Der p 21, a new important allergen derived from the gut of house dust mites*. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 758-767.	5.7	84
65	Evaluation by doubleâ€blind placeboâ€controlled oral challenge of the clinical relevance of IgE antibodies against plant glycans. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 891-896.	5.7	97
66	Different allergenic activity of grass pollen allergens revealed by skin testing. European Journal of Clinical Investigation, 2008, 38, 260-267.	3.4	61
67	Mast cell–derived proteases control allergic inflammation through cleavage of IgE. Journal of Allergy and Clinical Immunology, 2008, 121, 197-202.	2.9	43
68	Tolerization of a Type I Allergic Immune Response through Transplantation of Genetically Modified Hematopoietic Stem Cells. Journal of Immunology, 2008, 180, 8168-8175.	0.8	38
69	Disruption of Allergenic Activity of the Major Grass Pollen Allergen Phl p 2 by Reassembly as a Mosaic Protein. Journal of Immunology, 2008, 181, 4864-4873.	0.8	26
70	Microâ€arrayed wheat seed and grass pollen allergens for componentâ€resolved diagnosis. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1030-1037.	5.7	98
71	Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen. Journal of Immunology, 2010, 185, 943-955.	0.8	163
72	Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: Implications for specific immunotherapy. Vaccine, 2010, 28, 5075-5085.	3.8	67
73	Immunological Approaches for Tolerance Induction in Allergy. Current Topics in Microbiology and Immunology, 2011, 352, 1-26.	1.1	3

#	Article	IF	CITATIONS
74	Recombinant monoclonal human immunoglobulin E to investigate the allergenic activity of major grass pollen allergen Phl p 5. Clinical and Experimental Allergy, 2011, 41, 270-280.	2.9	17
75	Generation and epitope analysis of human monoclonal antibody isotypes with specificity for the timothy grass major allergen Phl p 5a. Molecular Immunology, 2011, 48, 1236-1244.	2.2	17
76	Expression of a Major Plant Allergen as Membrane-Anchored and Secreted Protein in Human Cells with Preserved T Cell and B Cell Epitopes. International Archives of Allergy and Immunology, 2011, 156, 259-266.	2.1	6
77	Cell-Based Therapy in Allergy. Current Topics in Microbiology and Immunology, 2011, 352, 161-179.	1.1	13
78	Persistent molecular microchimerism induces longâ€ŧerm tolerance towards a clinically relevant respiratory allergen. Clinical and Experimental Allergy, 2012, 42, 1282-1292.	2.9	13
79	Determination of allergen specificity by heavy chains in grass pollen allergen–specific IgE antibodies. Journal of Allergy and Clinical Immunology, 2013, 131, 1185-1193.e6.	2.9	5
80	Recombinant allergens for pollen immunotherapy. Immunotherapy, 2013, 5, 1323-1338.	2.0	12
81	Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. Immunobiology, 2013, 218, 884-891.	1.9	37
82	A contaminant trypsin-like activity from the timothy grass pollen is responsible for the conflicting enzymatic behavior of the major allergen Phl p 1. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 272-283.	2.3	2
83	Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis. Clinical and Experimental Allergy, 2013, 43, 1202-1216.	2.9	37
84	Identification of Der p 23, a Peritrophin-like Protein, as a New Major <i>Dermatophagoides pteronyssinus</i> Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. Journal of Immunology, 2013, 190, 3059-3067.	0.8	177
85	Multiple independent I g E epitopes on the highly allergenic grass pollen allergen P hl p 5. Clinical and Experimental Allergy, 2014, 44, 1409-1419.	2.9	17
86	Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. Journal of Allergy and Clinical Immunology, 2014, 133, 836-845.e11.	2.9	36
87	High-resolution crystal structure and IgE recognition of the major grass pollen allergen Phl p 3. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1617-1628.	5.7	19
89	Effects of Nasal Corticosteroids on Boosts of Systemic Allergen-Specific IgE Production Induced by Nasal Allergen Exposure. PLoS ONE, 2015, 10, e0114991.	2.5	12
90	Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. Journal of Allergy and Clinical Immunology, 2015, 135, 1207-1217.e11.	2.9	115
91	Infection with Rhinovirus Facilitates Allergen Penetration Across a Respiratory Epithelial Cell Layer. International Archives of Allergy and Immunology, 2015, 166, 291-296.	2.1	19
92	Marker allergens and panallergens in tree and grass pollen allergy. Allergo Journal International, 2015, 24, 158-169.	2.0	8

CITATION REPORT

~			n	
		ION		
ι.	ТАТ	IUN	IX F.F	PORT

#	Article	IF	CITATIONS
93	Flexible IgE epitope-containing domains of Phl p 5 cause high allergenic activity. Journal of Allergy and Clinical Immunology, 2017, 140, 1187-1191.	2.9	19
94	Allograft rejection is associated with development of functional IgE specific for donor MHC antigens. Journal of Allergy and Clinical Immunology, 2019, 143, 335-345.e12.	2.9	18
95	Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity. Scientific Reports, 2019, 9, 4006.	3.3	12
96	Recombinant Allergens for Immunotherapy. Advances in Experimental Medicine and Biology, 1996, 409, 85-93.	1.6	1
97	Recombinant Allergens. Advances in Experimental Medicine and Biology, 1996, , 185-196.	1.6	8
98	Characterization of Group 1 Allergens from Eleven Grass Species. Advances in Experimental Medicine and Biology, 1996, 409, 261-265.	1.6	6
99	Molecular Characterization Of Hor v 9. Advances in Experimental Medicine and Biology, 1996, , 269-277.	1.6	3
100	Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction Journal of Biological Chemistry, 1994, 269, 28323-28328.	3.4	74
101	Markerallergene und Panallergene bei Baum- und GrÄßerpollenallergie. , 2015, , 177-192.		1
102	Characterization of a birch pollen allergen, Bet v III, representing a novel class of Ca2+ binding proteins: specific expression in mature pollen and dependence of patients' IgE binding on protein-bound Ca2+. EMBO Journal, 1994, 13, 3481-6.	7.8	24